Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiology
Micrus Endovascular and Chemence Medical Products Sign Development Agreement for Liquid Embolic Products
May 9th, 2008
Micrus Endovascular Corporation (Nasdaq:MEND) and privately held Chemence Medical Products, Inc. announced the signing of an exclusive agreement to jointly develop liquid embolic products for neurovascular indications using Chemence's cyanoacrylate technology, development capabilities and intellectual property. Micrus Endovascular will be responsible for overseeing the regulatory and clinical process and will be the exclusive worldwide distributor for neurovascular products developed based on this collaborative agreement. Under the terms of the agreement, Micrus has made an upfront payment to Chemence and will make additional payments upon achieving certain development milestones....
Source: Health Business Week (2008-05-09)
|
|
Advertisement |
|
|
|
